Top

Published in:

01-02-2013 | Short Communication

Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance

Authors: Consolación Melguizo, Jose Prados, Raquel Luque, Raúl Ortiz, Ana R. Rama, Octavio Caba, Fernando Rodríguez-Serrano, Pablo J. Álvarez, Antonia Aránega

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2013

Abstract

Purpose

Multidrug resistance is one of the major obstacles to the successful treatment of non-small cell lung cancer (NSCLC). An ability to identify molecular markers of drug resistance in peripheral blood cells in order to better target treatment would therefore be extremely useful in selecting therapy protocols for patients. The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin.

Methods

Peripheral blood samples were obtained from lung cancer patients before and after chemotherapy and expression of the resistance gene in polymononuclear cells was detected by real-time reverse-transcription polymerase chain reaction. The results were correlated with treatment response and overall survival, which was calculated according to the Kaplan–Meier method.

Results

MDR1 expression levels in PMNs rose rapidly within 24 h post-administration of paclitaxel and carboplatin, whereas MRP and LRP expression levels remained unchanged. However, no significant correlation was observed between MDR1 expression and the patients’ survival or treatment response.

Conclusions

Modulation of MDR1 gene expression in PMNs after lung cancer treatment with paclitaxel and carboplatin cannot be used as a prognosis marker in these patients.

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594PubMed

Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15:50–61PubMedCrossRef

Hilgeroth A, Hemmer M, Coburger C (2012) The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies. Mini Rev Med Chem [Epub ahead of print]

Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N (2000) Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 59:329–335PubMedCrossRef

Laurençot CM, Scheffer GL, Scheper RJ, Shoemaker RH (1997) Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 72:1021–1026PubMedCrossRef

Berger W, Elbling L, Hauptmann E, Micksche M (1997) Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84–93PubMedCrossRef

Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798–1804PubMed

Wang M, Hong X, Sun Q, Li R, Yang Z, Chen G (2012) Establishment of animal model of a human lung adenocarcinoma drug-resistant cell line Anip973/NVB and investigation on mechanism of drug resistance. Zhongguo Fei Ai Za Zhi 15:146–151PubMed

Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar KR, Li WD (2011) Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J Int Med Res 39:1693–1700PubMed

10.

Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N (2001) Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93:584–589PubMedCrossRef

11.

Thatcher N, Heighway J (2010) Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 15:1034–1042PubMedCrossRef

12.

Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Comparing the relationship of taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181:267–273PubMedCrossRef

13.

Bogush TA, Konukhova AV, Ravcheeva AB, Zabotina TN, Kadagidze ZG, Bogush EA et al (2003) Inhibition of ABC-transporter(s)’ function in non-small cell lung cancer cells by platinum drugs. Antibiot Khimioter 48:11–15PubMed

14.

Berger W, Elbling L, Micksche M (2000) Expression of the major vault protein LRP in human nonsmall-cell lung cancer cells: activation by shortterm exposure to antineoplastic drugs. Int J Cancer 88:293–300PubMedCrossRef

15.

Rolff J, Dorn C, Merk J, Fichtner I (2009) Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J Oncol 2009:814140PubMedCrossRef

16.

Volm M, Koomägi R, Mattern J, Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251–257PubMedCrossRef

17.

Li X-Q, Li J, Chen P (2008) Expression and clinical significance of MRP1 and LRP mRNA in non small cell lung cancer. Pract J Cancer 23:145–147

18.

Baik SH, Jee BK, Choi JS, Yoon HK, Lee KH, Kim YH et al (2009) DNA profiling by array comparative genomic hybridization (CGH) of peripheral blood mononuclear cells (PBMC) and tumor tissue cell in non-small cell lung cancer (NSCLC). Mol Biol Rep 36:1767–1778PubMedCrossRef

19.

Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H, Yamakido M (1998) Expression of gamma-glutamylcysteine synthetase (gamma-CGS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 77:1089–1096PubMedCrossRef

Title: Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance
Authors: Consolación Melguizo
Jose Prados
Raquel Luque
Raúl Ortiz
Ana R. Rama
Octavio Caba
Fernando Rodríguez-Serrano
Pablo J. Álvarez
Antonia Aránega
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-2036-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Combination of three cytotoxic agents in small-cell lung cancer

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer